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ABSTRACT OF THESIS

Investigation of Amyloid β Oligomer Dissociation Mechanisms by Single Molecule
Fluorescence Techniques
Alzheimer’s disease (AD) is currently considered the most prevalent
neurodegenerative disease and places a large financial burden on society as healthcare
resources are limited and the disease does not have a cure. Alzheimer’s disease is
characterized by the presence of amyloid beta (Aβ) plaques and neurofibrillary tangles;
however current literature suggests Aβ oligomers are the main aggregating species leading
to AD symptoms. Therefore, the underlying cause of Alzheimer’s, accumulation of
amyloid beta, is currently being studied in hopes of developing treatment options. Our
research aims at determining the mechanism and kinetics of Aβ oligomer dissociation into
non-toxic monomers in the presence of denaturants or small molecule dissociators. These
highly active small molecule dissociators, selected from the Apex Screen 5040 library,
were previously identified by ELISA studies by the laboratory of Dr. Harry LeVine. We
have used fluorescence correlation spectroscopy (FCS) to characterize the size distribution
and mole fraction of synthetically prepared fluorescein labeled Aβ (1-42) oligomers. Our
FCS results show that in the presence of denaturants or small molecule dissociators,
oligomer dissociation may proceed by at least two different mechanisms; high order
cooperative dissociation and linear dissociation. A cooperative mechanism is more
desirable for therapeutics as oligomer directly dissociates into monomer rather than
through various oligomer intermediates. Our FCS studies show the most efficient
dissociators proceed through the cooperative dissociation mechanism. We also observed a
large retardation of the oligomer dissociation in the presence of gallic acid. We also started
preliminary work to develop a total internal reflection fluorescence (TIRF) spectroscopy
method to image Aβ (1-42) oligomers. This technique if successful will help to verify the
two distinct mechanisms seen by FCS or determine if there is one mechanism that occurs
at different rates as TIRF allows for faster analysis.
KEYWORDS: Alzheimer’s disease, Amyloid β, oligomer dissociators, fluorescence
correlation spectroscopy, total internal reflection fluorescence
spectroscopy, dissociation mechanisms.
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Chapter 1: Introduction
1.1 What is Alzheimer’s disease?
Alzheimer’s disease (AD) is the most prevalent slowly progressing irreversible
neurodegenerative disease and the sixth leading cause of death in the US.1 This disease
greatly affects the patient’s daily life due to symptoms such as memory loss, depression,
disorientation, confusion, behavior changes, poor judgement, and loss of motor functions.
Furthermore, Alzheimer’s places a huge economic burden on society as an individual
with Alzheimer’s cannot care for themselves and there is currently no cure for the
disease. The main risk factor for AD is advanced age therefore, as life expectancy
increases the economic burden also increases. In fact according to the annual Alzheimer’s
association report more than five million Americans currently have this disease and this
number continues to rise annually.1 For therapeutics to be developed we must understand
the complex pathology of this disease.
Alzheimer’s is characterized by two main pathologies, amyloid beta plaques and
neurofibrillary tangles, which begin to form within the brain about twenty years before
the onset of symptoms. While the formation of these pathologies begins in the
hippocampus, where memories are stored, the neuron damage spreads throughout the
brain, as shown in Figure 1.1, over time leading to severe brain atrophy.

1

Figure 1.1 Alzheimer’s disease leads to neuron death and brain atrophy. Reprinted from
reference: 2017 Alzheimer's Disease Facts and Figures Alzheimer's Association:
Alzheimers Dement, 2017; pp 325-373.

It is important to understand that the two pathologies are very different; while
amyloid beta plaques are formed by aggregated amyloid beta peptide; neurofibrillary
tangles, are composed of tau protein. As shown in Figure 1.2, these neurofibrillary
tangles form when tau becomes hyperphosphorylated causing tau to fall off the
microtubule, the track for intracellular trafficking of components, thereby destabilizing
the microtubule. Once the microtubule falls apart transport of vital components cannot
occur thereby leading to neuron death.
On the other hand, excess amyloid beta results from the loss of equilibrium of
amyloidogenic pathway due to excess β-secretase either causing overproduction or
impaired degradation of amyloid β. Therefore, the excess amyloid beta cannot be cleared
by the neuron leading to aggregated amyloid beta peptides which block synaptic neuron
signaling by binding to synaptic receptors or to the neuron cell membrane leading to
neuron death.
2

While both tau and amyloid β play an important role in AD pathology, our focus
is on Aβ oligomers as recent studies have shown that Aβ accumulation acts as the trigger
for tau.2 To back this claim, a recent study by Stancu et.al showed that mice with both
amyloid and tau pathology had more hippocampal atrophy than mice with only tau.
Furthermore, amyloid pathology was not affected or accelerated by the presence of tau.2
Aβ oligomers are able to activate tau pathology by binding to receptors inhibiting normal
function, this will be discussed in more detail later in this thesis.

Figure 1.2 The two main AD pathologies leading to neuronal death.
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1.2 Alzheimer’s disease stages
It is understood, thanks to the search for Alzheimer’s biomarkers that the
progression of Alzheimer’s disease is divided by three contiguous stages: the preclinical
stage (PCAD), mild cognitive impairment (MCI) and late stage Alzheimer’s disease
(LAD). Furthermore, these stages are often associated with the Braak scoring system for
neurofibrillary tau pathology in AD ; given a score from 0 to VI which correlates to the
amount of neurodegeneration and memory loss, Figure 1.3.3-4 The preclinical stage
correlates to a I to II on the Braak scale and can last 10 years or more. During PCAD
there are no clinical signs of Alzheimer’s disease, however there are signs of neuronal
degeneration. Therefore, the preclinical stage is currently known as the earliest detectable
pathological phase. While this stage is not a diagnostic stage as not all patients reach the
dementia state; it is important to understand to develop therapeutics. The mild cognitive
impairment state is characterized by III to IV on the Braak scale and an increased
presence of Aβ plaques and neurofibrillary tangles as well as cognitive decline faster than
expected given a patient’s age. However, the symptoms unlike LAD, do not dramatically
interfere with the patient’s everyday life. 5 The last stage of LAD is known to be a V to
VI on the Braak scale and is characterized by neurodegeneration in many parts of the
brain and severe cognitive decline. 3

4

Figure 1.3 Braak staging scale, areas affected by Aβ plaques are highlighted in red.
Reprinted from reference: Ovsepian, S. V., and O’Leary, V.B. Neuronal Activity and
Amyloid Plaque Pathology: An Update. Journal of Alzheimer’s Disease 2016, 49, 13-19.

1.3 History of Alzheimer’s disease discovery
Alzheimer’s disease (AD) was first described by German physician Dr. Alois
Alzheimer in 1901 when 51-year-old patient Auguste Deter, was observed for severe
memory loss and erratic behavior.6 When Auguste passed away, in 1906, Alzheimer
discovered lesions in the brain that caused significant neuronal shrinkage around neurons
via autopsy.6 While Alzheimer was the first to connect the symptoms of the disease with
the pathology Alzheimer did not name the disease. Interestingly, the term was coined in
1910 by German psychiatrist Emil Kraepelin7. The abnormal deposits, however, were
not fully characterized until 1984 when Glenner and Wong purified a 4.2 kDa protein
5

from β rich fibrils found in AD brain. They named this protein amyloid beta (Aβ). 8-9
Glenner and Wong also noticed that Down’s syndrome patients cognitively decline by
age 40 and hypothesized this was due to a connection to AD. Their hypothesis was that a
gene on chromosome 21, which is the chromosome in excess in Down’s, codes for
amyloid precursor protein (APP) which they believed undergoes proteolysis to form
amyloid beta. After autopsying brains of Alzheimer’s patients and Down’s patients they
saw the same pathology of amyloid plaques and neurofibrillary tangles in both cases
proving Down’s patients develop AD.10 Then in 1986, researchers discovered another
key protein to AD, tau protein and proposed that hyperphosphorylated tau falling off
assembled microtubules leads to neurofibrillary tangles which could be another main
suspect for causing Alzheimer’s.11
Alzheimer’s was further linked to APP in 1990 when an APP mutation, changing
glutamic acid to glutamine at codon 693 was discovered in severe cases of cerebral
hemorrhage with amyloidosis. This mutation disrupted the proteolytic processing of APP
increasing Aβ deposits.12-13 After this discovery three more missense mutations were
discovered in APP at codon 717 which changes valine to isoleucine, phenylalanine or
glycine which also disrupt the proteolysis.13 Lastly the discovery of another mutation
affecting APP proteolysis in familial Alzheimer’s involving presenilins 1 and 2 furthered
the understanding of how APP leads to Aβ.12 The amyloid cascade hypothesis, coined by
John Hardy in 1992, combined all these findings stating that Aβ, a product of APP
proteolysis, is the main causative agent of Alzheimer’s pathology leading to plaques and
then neurofibrillary tangles and neuronal death.13 This has been the widely accepted
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mechanism of Alzheimer’s disease since the 1990s and is described in the following
section.

1.4 Amyloid Cascade hypothesis
Before Aβ oligomers form, the amyloid precursor protein (APP), a type I integral
glycoprotein localized at the synapse, plasma membrane, endoplasmic reticulum (ER),
Golgi apparatus, endosomes, lysosomes, and mitochondria, must undergo proteolytic
cleavage.14 Even though the holo-APP protein has been shown to be neuroprotective
involved in neuronal cell growth, neuron to neuron communication and synaptic
plasticity; two very different pathways of APP processing exist: one normal
(nonamyloidogenic) and the other toxic (amyloidogenic) and proceed as shown in Figure
1.4.15
In the nonamyloidogenic pathway APP cleavage is catalyzed by α secretase
(present in the Golgi or at plasma membrane) which cleaves the APP to form the
membrane anchored fragment C83 (C-terminal APP with 83 amino acids) and sAβPPα
(soluble N-terminal APPα). C83 is then cleaved by  secretase (multimeric complex of
presenilin proteins) to form the amyloid precursor protein intracellular domain (AICD)
and extracellular P3 peptide (residues 17-40/42), which cannot form stable oligomers as
N-terminal residues 1-16 present in Aβ oligomers are absent in P3. Therefore, the
hydrophobic core is less protected, and the hydrophobic residues are exposed which
results in P3 being less stable than Aβ oligomers. Furthermore, sAβPPα levels are reduced
in AD patients and higher levels are found to have many benefits such as calcium
regulation and prevention of neurotoxic Aβ buildup.14
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On the other hand, in the amyloidogenic pathway, APP is first cleaved by β
secretase (BACE I, present in Golgi or endosomes) and then  secretase. When APP is
first cleaved by BACE a C99 peptide (C terminal APP with 99 amino acids) and sAβPPβ
(soluble N-terminal APPβ) are produced. Then C99 is cleaved by  secretase to form
AICD along with extracellular Aβ (1-40) and Aβ (1-42). Aβ then aggregates into
oligomers before forming plaques. Therefore, BACE is considered the rate limiting
enzyme in oligomer production as it is required for plaque formation and Aβ is
prefentially made in the Golgi as BACE is located there. However, two receptors called
SorLA (neuron sorting receptor) and LRP1B (low density lipoprotein receptor related
protein B) receptor counteract this process by sequestering the APP at the membrane to
block BACE, but these receptors are reduced in Alzheimer’s.14

Figure 1.4: APP cleavage pathways. The non- amyloidogenic pathway is nontoxic as Aβ
is not formed while the amyloidogenic pathway is toxic.
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1.5 Amyloid beta assembly
Amyloid beta peptide assembly exists in multiple forms which include monomer,
paranuclei, oligomer, protofibrils and fibrils, shown in Figure 1.4. While amyloid beta
assembly of monomer to oligomer is reversible the process is kinetically slow and not
well understood.16 Moreover, α helical monomer is neuroprotective but tends to selfassemble into neurotoxic oligomers. Since oligomers lack stable tertiary structure, they
spontaneously change conformation forming a more stable form called protofibrils.
Protofibrils look like beads on a string and are an intermediate of fibrils lacking a defined
β motif.17 Protofibrils then continue to spontaneously assemble into well-defined β sheet
rich fibrils ultimately leading to the hallmark amyloid beta plaques of AD.
It is important to note that there are two different main isoforms of Aβ seen in
AD: Aβ (1-40) and Aβ (1-42), which are 40 and 42 amino acids long respectively. While
the Aβ (1-42) only differs by two extra hydrophobic C terminus residues; the two
isoforms have very different biological behavior. Our studies focus on the Aβ (1-42)
isoform as it more commonly seen in plaques associated in AD.18 However, the distinct
differences between the assembly pathways of the two isoforms is important to
understand as these differences may explain why Aβ (1-42) levels are higher.19 While Aβ
(1-40) does form fibrils the rate of fibril formation is slower as the less hydrophobic Aβ
(1-40) is more stable. Furthermore, Aβ(1-40) more commonly exists as a mixture of
monomer, dimer, trimer, and tetramer in equilibrium, while Aβ (1-42) prefers to form
pentamer and hexamer units, called paranuclei, Figure 1.5.19 The paranuclei then selfassemble to larger oligomers which leads to faster fibril formation. The formation of the
paranuclei has been linked to the 2 extra hydrophobic residues in Aβ (1-41); Bitan, et.al
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showed the 41 residue Ile sec-butyl side-chain and the 42 residue Ala methyl sidechain to
be necessary for paranuclei formation and self-association.19

Figure 1.5: Amyloid beta (1-42) assembly pathway. Monomers spontaneously assemble
into paranuclei which self-assemble into oligomers which then form protofibrils before
forming fibrils.

1.6 Amyloid beta oligomer toxicity
While amyloid plaques formed from Aβ fibrils used to be considered as the main
toxic species in AD, it is now understood that these plaques also contain Aβ oligomers
which are the toxic component of plaques; thereby shifting the focus off of plaques.8, 20
Furthermore, unlike oligomers, plaques do not necessarily correlate with memory loss
and removing plaques does not stop or reverse AD progression.21 In fact several animal
studies show that oligomers injected into the brain cause decreased synaptic plasticity
10

impairing memory while fibrils and monomers do not have a significant effect; further
supporting oligomer as the toxic agent of AD.22 While the exact mechanism of Aβ
toxicity is still unclear the one thing that everyone can agree on is that toxicity is related
to the dysfunction of a mixture of processes related to Aβ oligomer accumulation.23
Oligomers interact with the neuron in one of two ways depending on the
oligomer’s size, as seen in Figure 1.6. While large oligomers (over 50 kDa) tend to bind
receptors; small oligomers (less than 50 kDa) tend to bind cell membrane on regions rich
in phosphatidylserine (PtdSer), cholesterol, or lipid rafts, causing the lipid bilayer to thin
resulting in pore formation and ion dishomeostasis.24

Figure 1.6: The main toxic species in AD are oligomers. While smaller oligomers cause
neuron death by forming pores in the neurotic membrane; larger oligomers bind to
synaptic receptors.
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Our research focuses on large oligomers that lead to synaptic dysfunction and
excitotoxicity by activating signaling cascades after binding to the synaptic receptors.
Processes that are affected by oligomers binding receptors include ion homeostasis, tau
phosphorylation, the cell cycle, axonal transport, insulin signaling, ER processing,
proteasome function, mitochondrial function, autophagy, and oxidation inhibition all
leading to apoptosis of neurons. Moreover, Aβ oligomers can target multiple receptors to
inhibit these biological processes including APOE/LRP1, RAGE, Frizzled, NMDA, α-7
nicotinic acetylcholine (α7nAChR), glutamate, insulin, LilrB2, EphB2, and prion protein
PrPC receptors, as seen in Figure 1.7. However, oligomers have higher affinity for
EphB2, glutamate, NMDA, and PrPC receptors which are concentrated on dendrites
suggesting oligomers prefer to bind dendrites over axons and due to this
neurotransmission is lost leading to synaptic dysfunction and neuron death.25
When oligomers bind NMDA (N-methyl-D-aspartate) and other glutamate
receptors, this binding event causes disruption of calcium signaling, decreased
kinase/phosphatase activity, and increased oxidative stress as levels of reactive oxygen
species increase. Glutamate excitotoxicity then occurs due to excess glutamate being
produced leading to decreased processing of glutamate to glutamine as glutamine
synthetase cannot keep up.26 Furthermore, levels of inhibitory neurotransmitter GABA
decrease as well, causing more excitotoxicity.26 Excitotoxicity eventually causes voltage
gated calcium channels to open causing calcium to first flood into the ER, but as levels
continue to rise, the calcium is then taken up by the mitochondria.27 When calcium levels
become more than the mitochondria can handle, the mitochondria permeability transition
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pore opens leading to mitochondrial apoptosis.27 This leads to synaptic dysfunction,
decreased synaptic plasticity, and neuronal apoptosis as the neuron is starved for ATP. 21,
28-29

Furthermore, lower levels of ATP have been shown to increase BACE levels, which

as mentioned in section 1.4 is the rate limiting step in Aβ production.30
Aβ binding nAChR leads to decreased acetylcholine (ACh) production due to
leakage of choline across the cell membrane leading to increased oligomer accumulation
and internalization.15, 21 Increased transport of oligomers into the neurons also occurs
when oligomers interact with RAGE (receptor for advanced glycation products) leading
to oxidative stress.15
When oligomers interact with APOE/ LRP1 (low density lipoprotein receptor
related protein) Aβ uptake by neurons is increased due to an increase in the rate at which
BACE binds APP.23 Furthermore, the presence of APOE-ε4 gene was discovered on
chromosome 19 which causes APOE to become overexpressed; therefore, individuals
with this overexpression have an increased risk of getting AD.31
Aβ oligomers binding to Frizzled receptors lead to inhibition of the Wnt
(glycoprotein that mediates cell communication, cell movement, polarity, axon guidance,
and synapse formation) this leads to tau hyperphosphorylation causing neurofibrillary
tangles and cell death.23 Lastly, when oligomers bind insulin receptors insulin signal
transduction is impaired causing decreased insulin production, increased oligomer
production, and decreased oligomer clearance thereby further reducing insulin signaling.
Because of this reduction of insulin signaling, AD is sometimes referred to Type 3
diabetes.29
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Figure 1.7. Possible oligomer receptor targets. Reprinted from reference: Kayed, R.;
Lasagna-Reeves, C. A., Molecular mechanisms of amyloid oligomers toxicity. J
Alzheimers Dis 2013, 33 Suppl 1, S67-78.

1.7 Recent studies of amyloid beta oligomers using single molecule analysis
Traditional methods for analyzing amyloid beta assembly and disassembly include
ThioT binding, SEC (size exclusion chromatography), AUC (ultracentrifugation), native
and SDS PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis), DLS
(dynamic light scattering) and ELISA (enzyme linked immunosorbent assay), however
many of these techniques are problematic as they require concentrations of Aβ that far
exceed physiological concentrations.16, 32-34 Furthermore, ThT, which was one of the
earliest ways to study Aβ, is not useful in studying early oligomerization as it only detects
the presence of β sheet structure in fibrils.35 SDS PAGE is also problematic as detergents,
such as SDS, can increase or decrease oligomerization. In SEC, monomer and small
oligomer interactions with the column matrix could lead to a shift in equilibrium
therefore large oligomers may dissociate to account for this effect leading to inaccurate
14

determination of oligomer molecular weight.33, 36 Finally, ELISA is problematic as exact
number and size of oligomers present cannot be determined.37 Since these traditional
biochemistry techniques have some drawbacks and Aβ is present in pM to nM
concentrations in the brain research has shifted to single molecule techniques, such as
fluorescence correlation spectroscopy (FCS).
One of the first FCS studies done on Aβ polymerization used rhodamine labeled Aβ
(1-40) to prove polymerization is cooperative as large aggregates proceed fibrils.
Tjenberg and collaborators saw fibrils forming after 40 minutes and a decrease in size
occurred to reach an equilibrium state within 2 hours. This study helped to lay the
foundation for using FCS as a technique to study Aβ polymerization and inhibition.38
Novo more recently focused on Aβ monomer aggregation to oligomer using FCS.
They discovered that aggregates of 28-88 monomers form once a critical aggregation
concentration (cac) is reached, and below the cac the sample remains monomeric.
Furthermore, their data again showed aggregation of monomer to oligomer is a
cooperative process. In this model, the aggregate size stays constant with increasing
time or concentration of Aβ (1-42), while only the number of aggregates increases.39
Another recent study using FCS to study Aβ aggregation observed Aβ (1-42) using a
five gaussian distribution to measure monomer, oligomer, protofibrils and fibrils
simultaneously. However, this model does not work well as it is difficult to distinguish
monomer from small oligomers and large particles tend to form due to aggregation.40
Another recent study using FCS to monitor Aβ assembly used ARCAM1 as a fluorescent
probe. Unlike ThT, ARCAM 1 binds small oligomers. They observed that the
fluorescence intensity increases 8-fold when Aβ is present. While the experiment was
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successful in determining oligomer assembly, the measured diffusion coefficient (3.4
μm2/s) proves protofibrils were still present in solution. 35
While these recent studies of oligomers tend to focus on understanding amyloid beta
association rather than dissociation; if we are going to stop AD progression we must
focus on dissociation as well. Very little research to date has looked at the dissociation
mechanisms. Furthermore, FCS on a mixture of several components is very complex and
data analysis becomes near impossible. Therefore, we also need a purer sample with only
two components.
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Chapter 2: FCS Studies Materials and Methods
2.1 Introduction
My research aimed at determining the mechanisms and kinetics of Aβ oligomer
dissociation and the effects of small molecule modulation by a series of APEX Screen
5040 compounds selected for by ELISA, by our collaborator Dr. LeVine.41-42 As
previously mentioned we choose to focus on oligomers because they are the main toxic
species in AD and tau pathology seen in AD cannot be present without Aβ. While the
compounds in this study were known dissociators the exact mechanism of dissociation
was not well defined, as ELISA is unable to accurately detect oligomer size, as
previously mentioned. By expanding this study to fluorescence correlation spectroscopy,
FCS, we can overcome these shortcomings of ELISA; as FCS allows us to monitor both
the hydrodynamic radius (size) and the concentration in real time giving us a glimpse of
how the molecule is dissociating. Furthermore, FCS allows us to use physiological
concentration (nanomolar to picomolar) therefore avoiding the increased aggregation of
Aβ observed at higher concentrations.
Previous research by the DeRouchey lab has shown that Aβ oligomer dissociation
proceeds by at least two different mechanisms; high order cooperative dissociation and
linear or non-cooperative dissociation. The cooperative mechanism is more desirable for
therapeutics as oligomer directly dissociates into monomer whereas in the linear
mechanism oligomer size and mole fraction progressively decrease forming oligomer
intermediates. By continuing our analysis of Aβ dissociation using FCS, we will be able
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to better understand these two mechanisms as well as probe for the existence of other
mechanisms.

2.2. Background of Fluorescence Correlation Spectroscopy
Fluorescence correlation spectroscopy, FCS, measures fluorescence fluctuations
of fluorescently labeled molecules as they diffuse through the confocal volume (or the
observed or in focus volume (femtoliter scale)) by Brownian motion. Since it was first
developed in the 1970s by Madge, Elson, and Webb; this technique has been used
extensively to determine size, kinetics, binding properties, concentration, or diffusion
speed of fluorescent molecules.43 We use this technique to study the dynamics of amyloid
β oligomer dissociation as it is non-invasive, has high resolution, and allows for low
sample volume and short sampling time.
The fluorescence intensity is measured by exciting the sample with an argon laser.
The beam is focused on a high numerical objective by a dichroic mirror and the
fluorescence emission from the sample is collected by the same objective. A high
numerical objective is used to obtain the best collection efficiency and therefore a high
spatial resolution. The emission is then focused on the detector by dichroic mirrors while
stray light is blocked by a pinhole, this setup is shown in Figure 2.1. Our FCS uses two
photomultiplier tube (PMT) detectors which requires a beamsplitter to divide the excited
photons between the two PMTs. The PMTs then collect the emission from the excited
sample and can be cross-correlated to correct for detector noise. When photons strike the
photocathode, electrons are released and accelerated in an electric field towards a series
of dynodes. Each dynode is about 100 V more positive than the previous therefore more
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electrons are generated at each and the signal is amplified, as shown in Figure 2.2. The
amplified signal is then used by the computer to generate an autocorrelation curve, G(τ),
which is used to determine sample characteristics.

Figure 2.1: FCS Setup. Reprinted from reference: Wöll, D., Fluorescence Correlation
Spectroscopy Studies of Polymer Systems. Springer Springer Series on Fluorescence
(Methods and Applications), 2016; Vol. 16
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Figure 2.2: Schematic of PMT. Reprinted from reference: Components of the confocal
microscope. http://www.ammrf.org.au/myscope/confocal/confocal/lasers.php

2.2.1 FCS Theory
As mentioned above FCS measures fluorescence intensity fluctuations due to
sample excitation. This fluorescence intensity, I (t), can be determined by measuring the
average intensity over time, <I (t)>, and the fluctuation in intensity, δ I (t). This can be
shown mathematically by: I (t) = <I (t)> + δ I (t). The autocorrelation function then gives
the correlation between intensity at time, t=0 and the intensity at a later time: G (τ) =
<δ I (t)•δ I (t+ τ)>t
<𝐼 (𝑡)>2 𝑡

. This can be used to determine the self-similarity of the fluorescence

fluctuations at lag time, τ, by measuring the signal at different lag times. As the lag time
increases the self-similarity decreases. We expect a good autocorrelation to have a lag
time of τ=0. The autocorrelation for diffusing molecules defined by a one component fit
can be represented as: 𝐺(𝜏) =
𝜏 −1
𝜏𝐷

)

• (1 +

𝜏
𝛾2 𝜏𝐷
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𝑁
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)−1/2 where N is the average number of molecules in the confocal
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volume (V), τD (τD= w2/4D) is the dwell time or time spent in the confocal volume and γ
is the structure factor, or axial ratio of the confocal volume (γ=z/w, where z is the height
of the confocal volume and w is the radius). The confocal volume, or volume of solution
in focus, can also be determined if the radius (w) and height (z) of confocal volume are
known using, V= π3/2w2z. For our measurements rhodamine 110 was used as a calibration
standard; with known diffusion coefficient of 440 μm2/s.44 The diffusion coefficient, D,
is then determined using: D= w2/ ατD, where α= 4 for one photon excitation and 8 for two
photon excitation.
However the autocorrelation function changes when there is more than one
diffusing species therefore for two-component fit the equation is: 𝐺(𝜏) =
(1 +

𝜏
𝜏𝐷1

)−1 • (1 +

1

𝜏
𝛾2 𝜏
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𝑁
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1

𝜏
𝛾2 𝜏

1

𝐷2

)−2 )) where pi is the

fractions of particles of species, i. This two-component fit is accurate for species that
have at least a 5-fold difference in size.35
The diffusion coefficient is one of the more important measurements obtained by
FCS as it is used to determine size of the molecules diffusing through the confocal
volume using the Stokes- Einstein equation: 𝐷 =

𝑘𝐵 𝑇
6𝜋𝜂𝑅ℎ

where kB is Boltzmann’s

constant, T is the temperature, η is the viscosity, and Rh is the hydrodynamic radius. It is
important to understand that as the diffusion coefficient increases as the size of the
fluorescent particle decreases (smaller molecules move faster). 43, 45-46
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2.2.2 FCS Triplet State
Single molecule detection requires high emission of excited fluorophores. This
leads to the probability of photons moving from the excited singlet to the triplet state
before relaxing back down to the ground state, Figure 2.3 B. The intersystem crossing of
singlet to triplet is nonradiative and slower (μs-ms) than the singlet to singlet (ns)
therefore there is a delay in fluorescence.47 This delay is due to the dye being between a
light emitting state (S1) and a dark state (T1). This leads to photo-blinking and the emitted
fluorescence and applied excitation to no longer be proportional.48 The triplet state
therefore causes a distortion of the autocorrelation curve, seen as an upswing, shown in
Figure 2.3A. Since the autocorrelation function changes in amplitude and shape due to
the triplet state the calculated N and τD would become inaccurate.49 Therefore, the
autocorrelation function must change in order to account for the triplet state effect and
1

the equation becomes: G triplet (τ) = ((1 – pt +(pt • exp (-τ/τt)))/ (1-pt)) • ( ) • ((1 +
𝑁

𝜏 −1
)
𝜏𝐷

• (1 +

𝜏
𝛾𝜏𝐷

1

)−2 )) where pt is the fraction of particles that are in the triplet state, t,

and is proportional to the amount of photoblinking. 45, 48, 50
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Figure 2.3: A. Shows FCS curve with triplet state. B. Shows Jablonski diagram of
intersystem crossing from excited singlet to excited triplet state.

2.3 Materials and Methods
2.3.1 Materials
The following were purchased from Sigma-Aldrich (St. Louis, MO); Amicon
ultra-15 centrifugal filter (50K cutoff), small molecules from APEX Screen 5040
compound library, 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), trifluoroacetic acid (TFA),
Tween 20, dimethyl sulfoxide (DMSO), polyethylene glycol bisphenol A epichlorohydrin
copolymer (PEG 15-20kDa), rhodamine 110 (R110) (Abs/Em maxima = 496/ 520 nm),
Alexa 488 (Abs/Em=495/519nm), Atto 488 (Abs/Em= 504/521nm), bovine serum
albumin (BSA), urea, and guanidine hydrochloride (GdnHCl). Polyethylene glycol 8
kDa, Eppendorf tubes, and Phosphate buffered saline (PBS) 10X were purchased from
Fisher Scientific (Waltham, MA). N-α-biotinyl-Aβ (1-42), fluorescein-Aβ(1-42)
(Abs/Em=494/521nm), Hilyte Fluor 488-Aβ(1-42) (Abs/Em = 503/528nm, fluorescein
(Abs/Em= 490/514nm), and Hilyte Fluor 488 (Abs/Em= 502/527 nm) were purchased
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from Anaspec (Fremont, CA). WT-Aβ (1-42) was purchased from rPeptide
(Watkinsville, GA). Poly-L-Lysine-graft-polyethyleneglycol) (PLL-g-PEG) was
purchased from SuSoS AG (Switzerland).

2.3.2. Sample Preparation for FCS studies
2.3.2.1 Preparation of 30nM fluorescein labeled Aβ (1-42) oligomers for FCS
First 9.1 μl of 0.2mg/ml of fluorescein labeled Aβ1-42 monomer was mixed with
5.1 μl of 1mg/ml wild type Aβ1-42 peptide in a 0.5 ml Eppendorf tube, which was
determined to bind minimal Aβ (Fisher 02681248), containing 25 μl HFIP. The use of
HFIP helps to break up aggregates so that the final sample is only monomer as HFIP
dissociated insoluble β sheet fibrils converting it into monomer. 51The mixture was then
dried to a thin film under filtered air to remove HFIP and 500 μl DMSO was added to
dissolve the dried film this solution was stored at room temperature in the dark and was
vortexed every 5 minutes. After 15 minutes the DMSO-solubilized fluorescein labeled
Aβ1-42 was diluted 100-fold into 50 ml of 50mM NaPi-150mM NaCl, pH 7.5 (an acidic
pH would lead to fibrils) (OFB) in a polypropylene tube and mixed rapidly and stored at
room temperature in the dark. After 30 minutes the assembly reaction was stopped by
adding 500 μl of 10 mg/ml polyethyleneglycol bisphenol A epichlorohydrin (PEG 15-20
kDa) copolymer that had been filtered through a 0.22 μm pore-size filter. The solution
was then concentrated by centrifugal filtration through a 50 kDa cutoff membrane at
3900 rpm at 8 °C in a swinging bucket rotor. After concentration, residual monomer was
washed through the membrane with 10 ml of OFB containing 100 μl PEG 15-20 kDa,
which helped to block the membrane from adsorbing the oligomers, and this wash step
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was repeated 1-5 times to reach the desired concentration. Oligomers were then stored in
50 μl aliquots at -80 °C.

Figure 2.4: Preparation of 1:4 FAM: WT Aβ (1-42) oligomers for FCS

2.3.2.2 Preparation of Amyloid beta monomer for FCS
5 μl of 0.2 mg/ml FAM-Aβ 1-42 in HFIP was mixed with 50μl HFIP in a 0.5 ml
colored Eppendorf tube. This was then dried to a thin film under air and an equivalent
volume of trifluoroacetic acid (TFA) was added and the mixture was incubated at room
temperature for 10 minutes in the hood to disaggregate seeds. The sample was then dried
to a thin film under air and the same volume of HFIP was added and mixed then dried
under air. Then film was then dissolved in 50μl of DMSO and used for FCS
measurements immediately (if frozen the sample would form oligomers).
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2.3.3 Instrumental setup
All FCS studies were performed on an ISS Alba FCS system coupled with a 1.2
numerical aperture (NA), 60X Nikon Ti-U microscope. The fluorescently labeled Aβ (142) was excited with a 488nm continuous wave laser diode and emitted radiation was
filtered by a 530 nm long-pass filter. This emission signal was detected by two separate
photomultiplier tubes (PMTs) and the measured autocorrelation functions were crosscorrelated and analyzed with Vista Vision 4.0 software (VWR, Radnor, PA). Three
different concentrations, 2.5 nM, 5 nM or 10 nM, of free rhodamine 110 (D= 440 μm2s-1)
were used to calibrate the confocal volume axial and radial dimensions (w and z) with a
60 second sample time for each measurement. A sampling frequency of 200,000 Hz with
a laser intensity of 130-180 μW was used for all measurements.

2.3.4 Time course of FAM-Aβ (1-42) oligomer dissociation by FCS
Prior to measurement by FCS Aβ (1-42) oligomer mixture was diluted 30-fold
from the 30nM stock solution with 1X PBS and loaded into a NUNC LabTek 8-well
microscopy chamber (Nalge Nuc, Penfield, NY), for a final volume of 300 μl. A series of
compounds from the APEX Screen 5040 compound library, which were previously
determined to be Aβ oligomer dissociators by LeVine37, 41-42, were dissolved in either DI
water or DMSO to make 1mM stock solution. For compounds dissolved in DMSO, Aβ in
pure DMSO at the same concentration used to dissolve the compounds (0.1 % v/v) was
measured for comparison. The stock was added in the appropriate amounts to the diluted
Aβ to give a final concentration of either 1μM, 3μM, 6μM or 10μM, each chamber was
then measured at room temperature over time. The effect of protein denaturants, urea, and
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Gdn HCl on Aβ oligomers was also studied. Each experiment was done in triplicate and
standard deviation was calculated for error bars.

2.3.5 Coating NUNC chambers before measurements by FCS
We also studied the effect of using different coatings on the NUNC chamber to
limit adsorption of the oligomers to the surface. Prior to measurements 300μl of 1mg/ml
Tween 20, PEG 8K, PLL-g-PEG, or PEG 15-20K was added to the chamber and allowed
to incubate overnight before being washed several times with 1X PBS. The diluted 30fold Aβ oligomer sample was then loaded into the blocked chambers and measured by
FCS over time. The effect of adding 66nM, 200nM, 250nM or 500nM WT-Aβ monomer
to 1nM FAM-Aβ monomer was also studied.33
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Chapter 3: FCS Results and Discussion
3.1 Proof of two-component FCS fitting
The accuracy of our FCS to perform a two-component fit was tested using Alexa
488, which has a similar diffusion coefficient as fluorescein. First, 10 nM free Alexa 488
was measured to determine the confocal volume parameters by fixing the diffusion
coefficient to 415 μm2/s (Rh=0.5 nm) which the known literature value for Alexa 488
standard dye.44 The calculated confocal volume radius (w) and height (z) obtained were
then used in subsequent measurements. Next, Alexa 488 labeled BSA was measured by
FCS and gave a diffusion coefficient of 67 μm2/s; which was in agreement with
previously reported diffusion coefficients and corresponds to hydrodynamic radius (Rh)
of 3.4 nm.52 Then three samples were prepared to test the two-component fitting accuracy
of the FCS containing three different ratios (1:1, 1:3, 3:1) of Alexa 488 free dye and BSA
bound Alexa 488. The samples were measured for 60 s at ~170 μW laser power and the
diffusion coefficients for Alexa 488 and BSA were fixed to the experimentally
determined values for each independently. Two component fits with only one free fitting
parameter, 𝑝1 , the fraction of component one, was used to experimentally determine the
ratio of free dye to labeled protein. The ratios obtained were then compared to the
theoretical ratios based on the sample preparation using statistical significance analysis,
which gave a p-value of 0.98. Since this is much greater than 0.05; we can say that there
is not a significant difference between the observed and theoretical fractions. However,
the theoretical data still does not perfectly match the experimental. This is explained by
the fact that our BSA is not 1:1 Alexa: BSA and contains 40% free Alexa 488 (Sigma
Aldrich). Therefore, we must multiply the observed ratios by the correction factor of 0.4.
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Since the ratios now match, we can conclude that the two-component fitting method is
accurate enough to distinguish between two particles with significantly different diffusion

Percentage of Alexa : BSA

coefficients.
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0

Alexa 488:BSA
Figure 3.1: Proving the two-component fitting method of FCS with Alexa and Alexa
tagged BSA. Blue represents Alexa 488 and grey represents BSA tagged with Alexa. The
fractions obtained by FCS are consistent with the mixture preparation once a correction
factor was determined for free dye.

3.2 FCS Determination of diffusion coefficient for monomer vs oligomer
Before we can determine the effects of small molecule modulation on Aβ
oligomer dissociation we must first determine the size differences between free
fluorescein, monomer, and oligomer which is shown in Figure 3.2 A. Using one-
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component fitting for free dye and monomer and two component fitting for oligomer we
determined the diffusion coefficients to be 425 μm2/s, 188 μm2/s, and 10 μm2/s
respectively. We then used the Stokes-Einstein equation to calculate the hydrodynamic
radius to be 0.5 nm for free dye, 1.2 nm for Aβ (1-42) monomer, and 25 nm for Aβ (1-42)
oligomers, which all agree with recent literature values.16, 44
We were able to prove the need for a TFA treatment during monomer preparation,
as mentioned in chapter 2.3.2.2, to obtain a sample of pure monomer as TFA breaks up
multimeric complexes. When TFA was not used, a two-component fit was found to be
necessary to describe the autocorrelation curves; where D2 fixed was to 10 μm2/s and the
sample was found to 20 % oligomer. After TFA treatment, shown in Figure 3.2 B, a onecomponent fit gave a diffusion coefficient of 188 μm2/s which corresponds to a Rh of 1.2
nm, which is in reasonable agreement with previously published Rh values of 0.9-1.4 nm
for monomers of Aβ.16 We were also able to confirm that the oligomer sample, prepared
as outlined in chapter 2.3.2.1, does in fact contain monomer and oligomer as the sample
cannot be fit by a one component fit, Figure 3.2 C. The experimentally determined values
for D for both monomer and oligomer were then used to fix the diffusion coefficients
during dissociation studies. Later I will discuss how in some samples this approach failed
and best fits were made by fixing D monomer and allowing D oligomer to vary;
suggesting that oligomers are shrinking in size over time. Lastly, unlike monomer or
oligomer, fluorescein is best fit with a one-component fit with a triplet state, Figure 3.2
D, likely due to self-quenching of the dye, which also explains why fluorescent counts
are observed to increase as oligomer dissociates.
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Figure 3.2: A) FCS showing free dye, Aβ (1-42) oligomers and Aβ (1-42) have different
diffusion rates. B. FCS one-component fit of Aβ monomer, Rh= 1.23 nm. C. FCS two
component fit of Aβ (1-42) oligomers, Rh=25.8 nm. Red line shows a one component fit
of oligomer and monomer mixture does not work. D) FCS curve of fluorescein, Rh= 0.5
nm, fit with a one-component fit with a triplet state.
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3.3 Importance of using PEG during oligomer concentration
As mentioned previously in section 2.3.2, a PEG (polyethylene glycol) polymer was
required to keep Aβ oligomers from binding to the filter during concentration. The PEG
used was 15-20kDa and synthesized with a bis-phenol A core, as depicted in Figure 3.3.
In fact, an FCS signal is not detected in the concentration flow-through; proving
oligomers do not leak through the filter membrane during the concentration step.
Previous FCS dissociation studies were performed on oligomers prepared without the
extra wash step discussed in chapter 2.3.2.1. This preparation resulted in mixtures of
approximately 50% oligomer and 50% monomer being formed (Figure 3.5 A). Our more
recent preparation, using the extra OFB with PEG washes, allows us to concentrate the
sample to approximately 80% oligomer (Figure 3.8). While there is concern that the
presence of PEG may modify the oligomer size or influence the reaction mechanism, it is
found to be necessary to prepare high fractions of Aβ oligomers for use in our
dissociation studies.

Figure 3.3: Structure of PEG synthesized with a bis-phenol A core.

3.4 Oligomer dissociation in DMSO using FCS
Aβ dissociation was first studied in dimethyl sulfoxide (DMSO) as DMSO is used for
dissolving the monomer film during the oligomer preparation as mentioned previously in
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section 2.3. Therefore, it is important to determine if DMSO not only inhibits oligomer
assembly but if it also leads to dissociation as well. Our results, as seen in Figure 3.4,
suggest that oligomer dissociation is dependent on DMSO concentration, as expected.
While 0.1% v/v is equal to the intrinsic dissociation rate, of 10% in 6 hours; when higher
concentrations such as 1% v/v or 3% v/v DMSO is used, dissociation is increased to 2530 % over 6 hours. While our results and previous work done by the DeRouchey lab
show that DMSO is a useful solvent for dissolving the monomer film during oligomer
preparation, it is important to use the lowest concentration possible as to not interfere
with oligomer formation. Furthermore, as 1% and 3% appear to dissociate at the same
rate, concentrations between 0.1% and 1 % should be tested to determine the best
concentration to use to preserve the oligomer stability.
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Figure 3.4. DMSO induced Aβ dissociation is DMSO concentration dependent. Aβ
dissociated 25-28% when 1% v/v DMSO or 3% v/v DMSO was present but showed
almost no dissociation in 0.1% v/v DMSO.
Furthermore, we also wanted to determine if 3% v/v DMSO dissociates Aβ oligomers
immediately, therefore we compared the fraction of oligomers present in the sample
before adding DMSO and after adding DMSO. As shown in Figure 3.5 B we observed an
8-10 % decrease in the oligomer fraction when DMSO is added, t1. Furthermore, Figure
3.5 B suggests that only the oligomer fraction is decreasing in 3% v/v DMSO.; as the data
is well described by a two-component fit where the monomer and oligomer size are kept
constant and only the fraction of oligomer is changing with time. This suggests a
dissociation mechanism where oligomers cooperatively dissociate leading to the near
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instantaneous formation of monomers as intermediate sized oligomers are not observed
by FCS.

Figure 3.5: A) Oligomer FCS fit before DMSO was added B) Dissociation of Aβ in
3% v/v DMSO after 6 hours, black= 0h, red=6hr, where size says constant at Rh= 30
nm and % oligomer decreases 28% in 6 hours.

3.5 Oligomer dissociation in 2,5 DHBA and oligomer stabilization by 3,4,5 THBA
Previously, our collaborator Dr. LeVine studied a Apex Screen 5040 compound
library using ELISA methods and identified potential dissociators.41-42 The most potent
dissociator in that study was found to be 10 μM 2,5 dihydroxybenzoic acid (2,5 DHBA),
Figure 3.6 A, therefore this was chosen as a starting point.41 The prepared 1nM 1:4 FlAβ:WT-Aβ was incubated with 10μM 2,5 DHBA and oligomer fraction was determined
with FCS two-component fits every hour for 6 hours. As shown in Figure 3.7 below 2,5
DHBA binds to Aβ oligomers and reacts with the peptide in a way that increases its
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dissociation around 20 %. Similar to DMSO, as shown in Figure 3.8, the size of
oligomers does not change when incubated with 2,5 DHBA only the fraction of
oligomers decreases. This data is consistent with cooperative dissociation where smaller
intermediates are not formed, and LeVine’s hypothesis, which stated that oligomers
decrease in number but not size in the presence of 2,5 DHBA.41
Next, we studied the effects of gallic acid (3,4,5 trihydroxybenzoic acid (THBA))
on oligomer dissociation. Despite gallic acid belonging to the same class as DHBAs, the
only difference being the extra hydroxy group (Figure 3.6 B), surprisingly the LeVine
study observed that gallic acid stabilized Aβ oligomers.41 As seen in Figure 3.7, we also
observe the stabilizing effects of gallic acid on Aβ by FCS. When the 1:4 Fl-Aβ/WT-Aβ
was incubated with 10μM gallic acid we observed that the dissociation after 6 hours was
equal to the intrinsic dissociation of Aβ. After a 24-hour incubation in gallic acid
interestingly, the fraction of dissociated oligomers was decreased only 43% compared to
the 90% dissociation observed in intrinsic Aβ oligomers.
Next, we investigated if this stabilization occurred in the presence of 10 μM 2,5
DHBA. FCS revealed that the Aβ dissociation with 10 μM 2,5 DHBA and 10μM gallic
acid was equal to the intrinsic dissociation of Aβ oligomer after a 6 hour incubation,
which was consistent with LeVine’s study.41 We therefore hypothesize that gallic acid
may be competing with 2,5 DHBA for the same binding sites on Aβ thus blocking 2,5
DHBA attachment and preventing dissociation.41 More experiments with time points
after 6 hours are needed to validate this hypothesis.
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Figure 3.6: Chemical structures for A. 2,5 DHBA and B. Gallic acid.

Figure 3.7: Percent of original oligomers left in solution after 0h, 3h, 6h and 24h
incubation in 10 μM 2,5 DHBA and gallic acid.

37

Figure 3.8: FCS curve of 1nM Aβ (1-42) oligomers incubated in 2,5 DHBA for 6h (red).
Oligomer fraction decreases 30% in 6 hours while the size of oligomers, Rh, stays
constant, consistent with a cooperative dissociation model.

3.6 Oligomer dissociation by protein denaturants
Next, we used FCS to monitor Aβ oligomer dissociation in the presence of
common protein denaturants, urea and guanidine hydrochloride (Gdn HCl), Figure 3.9.
These denaturants are known to cause protein unfolding by binding to the peptide bonds
in order to destabilize the peptide.53 Surprisingly, we see by FCS that these denaturants
dissociate Aβ oligomers differently than DMSO or 2,5 DHBA. As seen in Figure 3.10 A
the autocorrelation functions of the Aβ oligomers incubated in 8M urea are not well
described with two-component fits where both the monomer and oligomer diffusion
coefficients are fixed. Instead, the data is well-described by a model that suggests that
while the monomer fraction is increasing, the size of the oligomers is decreasing.
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As shown in Figure 3.10 B, oligomer size rapidly decreases 23 nm in six hours. In
fact, the size of oligomers decreases almost immediately when incubated in 8M urea;
decreasing from 31 nm to 16.6 nm, in the time between when urea was added and the
first measurement. After 6 hours, Rh decreases further to 7.9 nm. Interestingly, 8M urea
does not significantly change the total oligomer fraction from that of Aβ native
dissociation. Aβ oligomers were observed to intrinsically dissociate 10% in 6h while 8M
urea only increased the rate 10% as 20% dissociation was observed in the same amount
of time. Therefore, we hypothesize that urea is a partial linear dissociator, however more
studies are needed to prove this hypothesis.

Figure 3.9: Chemical structures of A. urea and B. Gdn HCl.
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Figure 3.10: A shows FCS result suggesting urea is a linear dissociator, as when D of
oligomer is fixed, blue, the fit does not describe the data well, so D oligomer must be left
free, red. B shows the summary of the change in Rh in 8 M urea over the 6-hour
incubation.

Next, Gdn HCl was tested to see if it is a strong linear dissociator or a partial
linear dissociator like urea. Aβ was first incubated with 1 M Gdn HCl, as shown in
Figure 3.11 A. However, these results do not necessarily prove Gdn HCl is a linear
dissociator; as when D oligomer was left free the best fit was essentially the same as the
fixed value. Therefore, the concentration was increased to 4M, Figure 3.11 B, and now it
is clear that Gdn HCl is a linear dissociator like urea, as fixing D oligomer to the standard
value for Aβ red curve does not work.
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Figure 3.11: A. FCS curve for Aβ linear dissociation induced by 1M Gdn HCl, blue,
however fitting for coperative dissociation also works, red. B. FCS curve for Aβ linear
dissociation induced by 4M Gdn HCl, proving this compound is in fact a linear fit.

As seen in Figure 3.11 and 3.12 while 1M Gdn HCl cannot be accurately
determined to be a linear dissociator, it still led to a significant 63% decrease in the
oligomer fraction as well as an 11 nm decrease in oligomer size. Furthermore, as seen in
Figure 3.12, 4M Gdn HCl decreased size of oligomers by 16nm and oligomer fraction by
54% in 6 hours. These results suggest a linear concentration dependent dissociation of Aβ
in Gdn HCl.
However, the next question was to determine if gallic acid influenced linear
dissociators or only cooperative dissociation by 2,5 DHBA. Therefore, 1nM 1:4 FlAβ/WT-Aβ was incubated with 10 μM gallic acid and 1M Gdn HCl, as shown in Figure
3.12. While gallic acid prevented the decrease in oligomer fraction our results show
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oligomers still shrink by 8-9 nm. Therefore, more experiments are needed to verify if
gallic acid stabilizes Gdn HCl induced Aβ oligomer linear dissociation.

Figure 3.12: A shows dissociation rate for Aβ oligomers in various concentrations of
Gdn HCl. B shows the decrease in Rh.

The last experiment with Gdn HCl was to increase the concentration to 8 M, when
incubated in 8M Gdn HCl oligomer Rh rapidly decreased from 26 nm to 2-3 nm, Figure
3.12. Furthermore, as shown in Figure 3.13 the FCS curve is best fit with a one
component fit, black curve, Figure 3.13 B. This proves large oligomers were no longer
present after 8M Gdn HCl treatment. Rather it appears that the large oligomers
completely dissociate into small oligomers of dimers or trimers. However, as mentioned
in Ch. 2.2 for a two-component fit to be accurate the molecules must have a 5-fold
difference in their size.35 Therefore monomer (Rh=1.2 nm) is still present and would still
be the predominate species but the size is not significantly different enough for the twocomponent fit to work and the presence of a few dimers/trimers biases the result.
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However, the formation of these dimers and trimers in 8 M Gdn HCl proves Gdn HCl is a
complete linear dissociator while urea is a partial linear dissociator.

Figure 3.13: A. FCS curve for Aβ oligomer linear dissociation to 2-3 nm small oligomer
intermediates in 8M Gdn HCl. B. FCS curve showing a one-component fit had to be
used, black. Red fit is two-component fit for monomer and large oligomers.

3.7 Oligomer dissociation by other ApexScreen 5040 compounds
As mentioned previously our collaborator Dr. LeVine previously identified
several potential Aβ dissociators by ELISA.41-42, 54 Since we saw similar results to Dr.
LeVine when comparing our FCS study of 2,5 DHBA induced dissociation of Aβ
oligomers, we selected three more compound classes from the Apex Screen 5040 library:
rhodamines, quinolines, and benzimidazoles. Previous studies have shown these
compound classes are useful probes of AD pathology as they have high affinity for
binding tau and a lower affinity for Aβ fibrils, however their effect on oligomers is not
well understood.55 Since DMSO was used to solubilize the compounds it served as a
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control for these studies. The first compound monitored by FCS for Aβ dissociation was
a benzimidazole derivative, Figure 3.14 A, labeled as 2C9 (number refers to location in
library). As shown in Figure 3.14 B, 2C9 was found to be a very potent dissociator using
FCS. As shown in Figure 3.14 B, incubation of Aβ oligomers in 10μM 2C9 resulted in a
20% decrease in oligomer fraction upon addition. After the 6-hour incubation 56% of the
oligomer fraction was observed to dissociate. Since the oligomer fraction decreased
rapidly in 10μM 2C9 we decided to do a dose response curve to better understand the
dissociation rate. As shown in Figure 3.15, the dissociation of oligomer is dependent on
2C9 concentration, as the fraction of oligomers decreases with increasing concentration
of 2C9 at each time point. Interestingly, the oligomers were not observed to dissociate
further between when 2C9 was first added, 0.5h, and the last time point at 5h, which was
not observed in the first experiment, Figure 3.14 B. The faster dissociation rate could be
attributed to the fact fresh 2C9 was prepared on the same day of the experiment.
Furthermore, the data was fit by fixing the D of both monomer and oligomer, consistent
with the corporative dissociation.
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Figure 3.14: A. General base structure of benzimidazole derivatives. B. Shows decrease
in oligomer fraction in 10μM 2C9 over 6 hours.

Figure 3.15: Dissociation time course of 1nM Aβ (1-42) oligomers in 2C9.
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Next, we used FCS to monitor Aβ dissociation in the presence of a rhodanine
derivative, Figure 3.16 A, 22D6. While rhodanines are known to be tau aggregation
inhibitors little is known about their interaction with Aβ oligomers.56 Surprisingly, our
FCS results show that dissociation did not occur; as DMSO and 22D6 had the same
dissociation rate, Figure 3.16 B. These results are explained by the fact that the ester form
(inactive) was used rather than the acid form (active) and therefore giving us a
comparison for the other ApexScreen 5040 compounds.

Figure 3.16: A. General base structure of rhodanine derivatives. B. Shows 0.1% v/v
DMSO and 10μM 22D6 have the same dissociation rate.

Previously, Dr. LeVine and collaborators used ELISA studies to show that
hydroxyquinolines inhibit Aβ oligomer formation but do not dissociate Aβ oligomers
once formed.42 Typically, these compounds would react with Aβ by chelation however
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his results proved that this was not necessarily the only means of inhibition.42 Therefore,
we decided to use FCS to investigate if quinoline derivatives, Figure 3.17 A, 39H8 and
39A8 would dissociate oligomers. FCS revealed that both quinoline derivatives
cooperatively dissociate Aβ as oligomer size remained constant while oligomer fraction
decreased, Figure 3.17 B. Furthermore, incubation of Aβ oligomers in 10 μM 39A8 or
39A8 result in a 45-53% decrease of the oligomer fraction upon addition. After a 6-hour
incubation 65-71 % of the oligomer fraction was observed to dissociate. We also studied
dose response with these quinoline derivatives, Figure 3.18. Similar to 2C9, dissociation
with 39H8 is concentration dependent as the dissociation was increased at each time
point with increasing concentration. Interestingly, for 39A8 6 μM was more potent than
10 μM, therefore more studies need to be done to confirm the concentration dependence.

Figure 3.17: A. General base structure for quinoline derivatives. B. Shows dissociation
rate for Aβ oligomer incubation with 10 μM 39H8 and 10μM 39A8.
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Figure 3.18: A. Dissociation time course of 1nM Aβ (1-42) oligomers in 39A8. B.
Dissociation time course of 1nM Aβ (1-42) oligomers in 39H8.

3.8 Coating NUNC Chamber
Due to a series of unexpected results and a sudden decrease in fluorescent
intensity with time, Figure 3.19 A, we assumed our sample was photobleaching.39
Normally we see fluorescence increase as oligomers dissociate due to increased free dye
in solution. As this change occurred after a laser realignment, our first thought was that
this decrease in fluorescence was caused by having the laser power set too high.39 To test
for the appropriate power level, we measured Aβ oligomers at various laser powers, 8156μW, Figure 3.19 B. However, we still see the fluorescence decrease occurring at the
about same rate, 60-80%, for each laser power tested, even at a very low laser power of 8
μW.
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Figure 3.19: 1nM Aβ oligomer fluorescent counts decrease 80% with time, at ~170 μW.
B. Testing photobleaching at various laser powers.

Next, to try to verify that the dye was photobleaching we measured a series of free
dyes at 156 μW, Figure 3.20. We compared the free fluorescein (FAM) to R110, Alexa
488 and Atto 488 to find a dye less susceptible to photobleaching, each dye was
measured at 10nM concentration. However, we found free fluorescein was not
photobleaching and in fact the fluorescence increased with repeated FCS measurements.
Next, we decided to further test if the dye was photobleaching by measuring free FAM as
well as free Hilyte 488 at various laser powers, as Hilyte 488 labeled Aβ can also be
purchased from Anaspec and Hilyte 488 is known to be less susceptible to
photobleaching than FAM. However as seen in Figure 3.21 FAM is just as stable as
Hilyte 488 at laser powers below 200 μW.
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Figure 3.20: A. Comparison of the change in fluorescent counts with repeated
measurements of various free dyes at 156 μW.
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Figure 3.21: A. Comparison of free FAM at various laser powers at t=0min and after 6
consecutive measurements (t=30min). B. Comparison of free Hilyte 488 at various laser
powers at t=0min and after 6 consecutive measurements (t=30min).

Therefore, we concluded that the fluorescence decrease was not due to
photobleaching and could be due to a failed Aβ oligomer preparation as the oligomers
tested were from a new batch. To verify this, we prepared and measured an Aβ monomer
sample, Figure 3.22. We again saw an 80% decrease in fluorescent counts within 5
minutes. Since we still saw a fluorescent count decrease in our monomer sample the
decrease in fluorescence is not likely due to a failed oligomer preparation.
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Figure 3.22: 1 nM Aβ (1-42) monomer decreases in fluorescence with repeated
measurements at 156 μW laser power.

A recent study by Wennmalm, et.al., found that Aβ decreases in fluorescence over
time during FCS, due to Aβ adsorbing to the sample holder.33 They proved this
hypothesis by observing that diffusion increases over time as large particles adsorb to the
glass and smaller particles stay in solution, Figure A1. As seen in Figure 3.23 A we
observed the same effect for the oligomer at various laser powers study, except for
sample at 12 μW. Additionally, we see that concentration of oligomers decreases rapidly
at each laser power further confirming that the oligomers could be adsorbing to the
sample holder, Figure 3.23 B. Interestingly, the concentration for the sample at 22 μW
decreased the most, ~70%; due to this large discrepancy, this measurement is likely
inaccurate and should be repeated.
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Figure 3.23. Diffusion speed increases (A) and concentration decreases (B) with time for
oligomer.

Since Wennmalm, et.al., was able to eliminate this issue by precoating the sample
holder with poly-l-lysine PEG, Figure A1, our next series of tests were to see if we could
find an effective coating to limit Aβ oligomer from adsorbing to the sample holder during
our dissociation studies, Figure 3.24.33 However, our results showed that none of the
coatings tested improved the decrease fluorescence.
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Figure 3.24. Coating sample chamber with different polymers (1 mg/ml) to limit
adsorption of Aβ to the sample holder was unsuccessful, as fluorescence still decreases
(A) and the diffusion coefficient increases (B).

We also tested PLL-PEG on the minute time scale as Wennmalm, shows Aβ will
bind to the untreated chamber within seconds, Figure A1. Unlike this study our results
show PLL-PEG did not improve the decrease in fluorescence or increase in diffusion
coefficient, Figure 3.25. Therefore, it can be concluded that the PLL-PEG might be
improving the amount of Aβ binding but does not completely block the oligomers from
binding to the NUNC chamber.
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Figure 3.25. 1mg/ml PLL-PEG coating does not appear to stop oligomers from binding
the sample holder as the decrease in fluorescence (A) and increase in D (B) still occurs.

Wennmalm, et.al., also stated that if a higher concentration than 200nM Aβ was
used then the sample would not adsorb to the sample chamber as the excess Aβ blocked
further binding. As seen in Figure 3.26, when we tested various concentrations of WT Aβ
monomer added to 1nM FAM-Aβ monomer sample, the drop in fluorescent counts still
occurs. Additionally, the concentration increases as the amount of WT-monomer present
increases. This could be due to excess WT-monomer interacting with the FAM-monomer
instead of the sample holder which would also explain the decrease in fluorescence. This
experiment was not repeated in an oligomer sample as it was unsuccessful.
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Figure 3.26: Coating sample chamber with excess WT-monomer. A shows fluorescence
still decreases and B shows decrease in concentration.

While our results did not match up to the Wennmalm study, our data still points to
oligomers binding to the sample holder. Since their study showed PLL-PEG blocking Aβ
binding we decided to use a glass slide to replicate their study and prove that the extra
surface area of the NUNC chamber is why oligomers still bind, even with PLL-PEG
coating. However, as shown in Figure 3.27, 1nM Aβ did not bind to the untreated glass
slide as expected, as fluorescence and concentration increased in the sample on glass and
decreased in the sample in the NUNC. As Wennmalm showed the oligomers binding to a
glass cover slip within 5 minutes we next repeated our measurements using this faster
time scale to see if our time scale was not quick enough to observe the oligomer binding.
Furthermore, we wanted to compare the concentration used by Wennmalm, 30nM, to the
one we use, 1nM, as increased concentration could explain an increased rate of
absorption. As shown in Figure 3.28, Aβ oligomers do not appear to bind to the glass
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slide at either concentration as counts and concentration are increasing, while the
diffusion coefficient stays relatively constant. Interestingly our results from FCS do not
match the expected concentration, even at time zero. As mentioned earlier Wennmalm,
et.al., observed that at 200nM Aβ the oligomers coat the glass and the PLL-PEG coating
was not needed, which could explain why the oligomers are not binding to the glass in
our experiment. However, it is unlikely that the Aβ would bind so quickly that the
concentration decrease cannot be observed. Since the confocal volume was calibrated
with 10nM R110 free dye the measurement might not be accurate enough for the 30nM
Aβ sample; resulting in a lower value for concentration. As mentioned in Ch. 2 we used
PEG 15-20k during the concentration of oligomers however this was not used by
Wennmalm. Therefore, the PEG coating the oligomer could explain why our oligomers
do not bind to the glass slide. However, as oligomers do still bind to the plastic NUNC
moving forward it would be better to only use the glass slide.
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Figure 3.27: A. Fluorescence counts increase for 1nM Aβ oligomer on glass slide and
decrease for 1nM Aβ oligomer in NUNC chambers. B. Concentration is stable for 1nM
Aβ oligomer on glass slide but decreases for 1nM Aβ oligomer in the NUNC chamber.
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Figure 3.28: A. Fluorescence is stable for Aβ oligomer on glass slide at both 1nM and
30nM concentration. B. Unnormalized fluorescent intensity for 1nM and 30nM Aβ on a
glass slide. C. Diffusion of Aβ oligomers remains constant on a glass slide at both 1nM
and 30nM concentration D. Concentration increases with repeated measurements for Aβ
on a glass slide at 30nM and is stable for Aβ at 1nM concentration.
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Chapter 4: Developing a TIRF imaging technique of Aβ (1-42) oligomers
4.1 Introduction
While FCS is useful for studying the mechanism of oligomer dissociation,
limitations exist. The main limitation of FCS is that FCS only gives average diffusion of
all molecules in the confocal volume. However, it is probable that all oligomers in our
sample are not the same size. This chapter will outline the development of a TIRF
method to measure Aβ (1-42) oligomers to overcome this limitation of FCS. By
expanding our oligomer dissociation studies with TIRF we can analyze dissociation
across multiple individual oligomers within the same sample. This would validate if there
are two distinct dissociation mechanisms as observed by FCS or if there is only one
mechanism occurring at different time scales not able to be distinguished by FCS.

4.2. Background on TIRF
Total internal reflection fluorescence microscopy, TIRF, is a technique used for
the visualization of biological molecules. TIRF differs from traditional epifluorescence
where the whole sample is excited, as the laser beam position is changed at the objective
focal plane in TIRF to allow for less sample to be excited, Figure 4.1. This decreases
background fluorescence providing for out of focus fluorescence to be eliminated and
thereby decreasing the signal to noise ratio and out of focus fluorescence.
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Figure 4.1: Schematic showing difference between epifluorescence vs TIRF. Reprinted
from reference: Ravier, M., et.al. Imaging a target of Ca2+ signaling: Dense core granule
exocytosis viewed by total internal reflection fluorescence microscopy. Methods 2008,
46:3. 233-238.

As shown in Figure 4.2, during TIRF the laser beam is focused at the back of the
objective focal plane and is then focused on to the glass cover slip. The laser beam then
propagates through the transparent glass medium with a high index of refraction until it
interacts with the sample solution which has a lower index of refraction. These refractive
index differences between the glass and the sample therefore determine the critical angle
of reflection, given by Snell’s law: ϴcritical = sin-1(ηg/ηs). For the total internal reflection,
where all light is reflected to the glass, to be achieved the incident angle must be greater
than the critical angle. Although the light will no longer be prorogating into the sample
the small amount of the reflected light that penetrated at the interface creates an
evanescent wave (electromagnetic field) in the sample. This evanescent wave then
propagates parallel to the surface in the plane of incidence and its frequency is equal to
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the excitation frequency. However, this wave decays with increasing distance from the
interface therefore only fluorophores within 200 nm of the coverslip are excited, given by
E(z)= E (0) exp(-z/d), where E(z) is the energy at distance z from the interface, E (0) is
energy at the interface, and d is the penetration depth. Also, d is dependent on the
wavelength of incident light, the angle of incidence and the refractive indices, given by:
2
2
2 1/2
d= λi / 4π (ng sin θ - ns ) . Then dichromic mirrors direct the emission beam to the

camera to create an image as seen in Figure 4.3. 57-58

Figure 4.2: Schematic showing theory of total internal reflection fluorescence. Reprinted
from reference: http://biointerfaces.mcmaster.ca/instruments/tirf/

The TIRF we used is equipped with a CMOS (complementary metal oxide
semiconductor) camera mounted on the microscope controlled by Metamorph software.
CMOS uses an array of light sensitive pixels to generate an image. CMOS is advantageous
over other cameras as it uses less power, has a fast response time, and each pixel is
amplified separately resulting in good sensitivity. Using this technology, we can observe
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and measure the dissociation of each individual oligomer on the glass cover slip surface
simultaneously, instead of the general trend of all oligomers in solution. This can help to
validate previous findings of two distinct mechanisms of oligomer dissociation.

Figure 4.3: Schematic of TIRF instrumental set-up. Reprinted from reference: Lord, S.
J.; et.al. Single-Molecule Spectroscopy and Imaging of Biomolecules in Living Cells.
Analytical chemistry 2010, 82 (6), 2192-2203.

4.3 Materials and Methods
4.3.1 Materials
The 35mm plastic Petri Dishes with glass cover slip bottoms were purchased from
Cell E&G. The Biotin-PEG-Silane was purchased from Lysan Bio Inc. The neutravidin
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protein was purchased from Thermofisher. The following Aβ (1-42) peptides were
purchased from Anaspec: FAM-Labeled Aβ(1-42), WT Aβ (1-42) and Biotin-Aβ(1-42).

4.3.2. Preparation of 1:1:4 biotin labeled: FAM labeled: unlabeled oligomers for
TIRF analysis
First 1.82 μl of 0.2mg/ml of biotin labeled Aβ1-42 was mixed with 1.82 μl of 0.2
mg/ml FAM labeled Aβ and 1.02 μl of 1mg/ml wild type Aβ1-42 peptide in a 0.5 ml
colored Eppendorf tube containing 5 μl HFIP. This was then dried to a thin film under air
and dissolved in 5 μl TFA to disaggregate seeds and dried to a film. The film was then
dissolved in 5 μl HFIP and dried once more to remove residual TFA. Then 100 μl DMSO
was added to dissolve the dried film and the solution was stored at room temperature in
the dark and was vortexed every 5 minutes. After 15 minutes the DMSO solubilized Aβ142 was diluted 100-fold into 10 ml of 50mM NaPi-150mM NaCl, ph7.5 (OFB) in a
polypropylene tube and mixed rapidly and stored at room temperature in the dark for 30
minutes and 100 μl PEG 15-20k was added to stop the reaction. Oligomers were then
stored in 1 ml aliquots at -80 °C and were mixed in a 2:1 ratio with 2mg/ml biotin-PEGsilane for TIRF.

4.3.3 Glass Modification procedure for protein immobilization
To eliminate background fluorescence and to enable biotin-PEG-silane binding to
the glass, the 35mm Petri dishes that were used for TIRF measurements were modified
with base and acid, Figure 4.4. First the petri dishes were sonicated for 1 hour at 45°C in
5M NaOH to convert the silicon dioxide to siloxane. Next the dishes were rinsed in hot
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water and ethanol several times before being sonicated again in 0.1 M HCl, to covert
siloxane to silanol. Then after rinsing in hot water and ethanol again the petri dishes were
put in a plasma cleaner for 4-5 minutes to remove residual organic contaminates. The
dishes were then imaged using TIRF to check for background fluorescence before being
used for experiments with Aβ.

Figure 4.4: Glass surface modification for attachment of Bio-PEG-Silane. Reprinted
from reference: Nicholas, M. P.; Rao, L.; Gennerich, A., Covalent immobilization of
microtubules on glass surfaces for molecular motor force measurements and other singlemolecule assays. Methods Mol Biol 2014, 1136, 137-69.
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4.3.4 Biotin-Neutravidin linker chemistry protocol
First 300 μl of 2 mg/ml Biotin-PEG-Silane solution was added to a clean and
modified petri dish and allowed to incubate at room temperature for 30 minutes. Then the
petri dish was washed with ethanol several times. Then 300 μl of 0.1 mg/ml neutravidin
in PBS buffer (pH 7) was added and allowed to incubate for 2 hours. After rinsing out the
neutravidin several times with PBS buffer (pH 7), 300 μl of 2:1 v/v 2 mg/ml biotin-PEGsilane: prepared 0.03μM 1:1:4 biotin-Aβ (1-42): FAM-Aβ (1-42): WT Aβ (1-42)
oligomers were added and incubated for 30 minutes. The 2:1 ratio of biotin to labeled
oligomers helped to eliminate non-specific binding by blocking the surface of the glass
cover slip. Furthermore, controls were run to verify binding efficiency; the first was
without adding the Aβ and the second was one where 1:10 Aβ: Biotin was used.
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Figure 4.5: Immobilization of prepared Aβ (1-42) oligomers for TIRF.

4.3.5 Instrumental Setup
All images obtained using objective style total internal reflection fluorescence
microscope equipped with an inverted microscope (Olympus ix83). Samples were excited
with 488nm laser which was focused onto the Olympus, 1.5 NA, 60X, oil immersion
objective. To obtain TIRF the beam was focused on the back aperture of the objective
lens with a stepper motor. 59 The CMOS camera then detected the signal to generate an
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image using MetaMorph software (MDS, San Jose, CA). The camera was set to a frame
read time of 200 ms and the binning was set to 4 X 4 (250 pixels X 250 pixels).
Autofocus was also used to eliminate drift.

4.4 Results and Discussion
The major difference between our FCS studies and our TIRF studies is that
oligomers are fixed on a glass cover slip for TIRF instead of flowing free in solution. To
attach the oligomers to the glass we must first “clean the surface” as outlined previously
in 4.2.3. This helps not only to remove contaminants but by using HCl and NaOH we can
convert silicone dioxide to siloxane then to silanol, as silanol is more reactive with the
silane.60 Without this cleaning step it would be impossible to get the Bio-PEG-Silane to
attach to the glass and even it did we would not be able to distinguish sample from
contaminates, Figure 4.6.

Figure 4.6: A shows glass cover slip that had not been cleaned and B shows one that has.
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The first experiment with Aβ and TIRF was a negative control in order to
determine the order components should be added in order to observe the immobilized Aβ.
At first, we used unlabeled biotin-Aβ (1-42) oligomers instead of Biotin-FAM-Aβ (1-42)
to prove that the protein must be labeled in order to be observed by TIRF. The procedure
in Ch. 4.3.4 was followed however, due to the fact the oligomers were not fluorescently
labeled, we had to add 1mg/ml streptavidin 488 after allowing the oligomers to bind. This
extra step, as seen in Figure 4.7, resulted in a high amount of background fluorescence.
Therefore, to eliminate the extra background fluorescence, we changed the oligomer
preparation to make 1:1:4 biotin Aβ: FAM Aβ: WT Aβ, as outlined in Ch. 4.3.2, instead
of using 1:1 biotin Aβ: WT Aβ.

Figure 4.7: Epifluorescence image where unlabeled biotin-Aβ (1-42) with streptavidin
488 was attached to the glass cover slip.

After we optimized the cleaning procedure and the oligomer preparation
procedure we imaged a series of controls. As shown in Figure 4.6, the cleaning procedure
was efficient, and nothing appears in the TIRF if fluorescently tagged protein is not
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added. As shown in Figure 4.8 B, the 1:1:4 Bio-Aβ/Fl-Aβ/WT-Aβ oligomers will attach
to the neutravidin functionalized surface, however, the data analysis is difficult due to the
number individual oligomers in our sample. Therefore, to limit the non-specific binding,
we decided to dilute the Aβ before attaching it to the coverslip. We first used a 10:1 ratio
of biotin-PEG-Silane: 30 nM 1:1:4 Bio-Aβ/Fl-Aβ/WT-Aβ, however as seen in Figure 4.8
C this ratio was too high. Next, we decided to lower the ratio to 2:1 Biotin-PEG-Silane:
Aβ, as seen in Figure 4.8 D, which was then used for subsequent TIRF studies.

Figure 4.8: TIRF controls. A shows a sample where only biotin and neutravidin were
added to the cover slip. B shows 30nM Aβ bound to the cover slip. C shows 10:1 BiotinPEG-silane: Aβ bound to the cover slip. D shows 2:1 biotin-PEG-silane: Aβ bound to the
cover slip.
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After establishing a dilution factor, the prepared 1:1:4 Bio-Aβ/Fl-Aβ/ WT-Aβ was
incubated with 40μM 2,5 DHBA and imaged with TIRF every 30 minutes for 6 hours.
This concentration was chosen as it was assumed that a higher concentration would be
necessary as bound oligomers would be more difficult to dissociate then those free in
solution. As shown in Figure 4.9, data analysis using ImageJ is challenging. Typically,
we would select the bound oligomers in time frame 1 and the software would then
measure all frames simultaneously. So far, we have not been able to effectively use this
software due to a drift effect. This drift effect could be due to the camera moving to a
new spot on the slide with each time point, however focus hold was used so that should
not be occurring. Another factor could be due to photobleaching of the FAM dye, which
we have observed with FCS, where we see the fluorescent counts decrease due to
quenching of fluorescein as oligomers dissociate. To fix this problem we could try a
different fluorescent probe less susceptible to photobleaching. Another cause for the drift
could be that as oligomers dissociate and detach from the glass cover slip free oligomer
in solution bind to re-establish the equilibrium; this could be prevented by adding extra
washes after binding oligomers or blocking the surface. Unfortunately, until more
experiments can be done where the drift effect is eliminated no conclusions can be made.

71

Figure 4.9: Problem with TIRF data analysis is that with each time point the slide moved
slightly. A shows t=0, B shows t= 30 mins C is t= 6 hours. Red dots= oligomers bound
on slide. Yellow circle is what is being measured.
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Chapter 5: Conclusions and Future Work
5.1 Conclusions
Amyloid beta oligomers are widely considered to be the main toxic aggregating
species leading to Alzheimer’s disease pathology. For therapeutics to be developed it is
necessary to understand how this protein aggregates and dissociates. The focus of this
thesis was therefore to understand Aβ oligomer induced dissociation by select small
molecules from the Apex Screen 5040 compound library. The compounds studied had
been previously determined to be potent dissociators but little was understood about the
dissociation mechanism, as the technique used, ELISA, is unable to give such
information.41-42 Using FCS, we have found that these select small molecules from the
Apex Screen 5040 library are able to bind to preformed amyloid beta oligomers causing
them to lose stability. Furthermore, our data suggests that there are two possible
dissociation mechanisms: higher order cooperative dissociation and linear dissociation,
Figure 5.1.

Figure 5.1: Proposed mechanisms of Aβ dissociation. A) Linear dissociation B) High
order cooperative dissociation.
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When Aβ oligomers were incubated with DMSO, 2,5 DHBA, 2C9, 39H8 or 39A8
oligomer size remained constant while the fraction of oligomers in solution decreased.
These results line up with a high order corporative dissociation model where oligomer
immediately converts into monomers. On the other hand, when Aβ oligomers were
incubated in urea, or Gdn HCl both oligomer fraction and size decreased, lining up with a
linear dissociation model. It is obvious that a cooperative mechanism is more desirable
for therapeutics as oligomer directly dissociates into monomer whereas in the linear
mechanism toxic oligomer intermediates are formed. Furthermore, our data suggests that
Aβ oligomer dissociation is dependent on dissociator concentration for both corporative
and linear dissociators. However, more experiments are needed to fully understand the
concentration dependency as this will provide insight into dissociation kinetics.
While our data supports these proposed mechanisms when we consider the
assembly pathway mentioned in section 1.4 these models do not make physical sense. To
form oligomer, Aβ (1-42) firsts forms paranuclei; which are pentamers or hexamers.
Then these paranuclei self- assemble to form large oligomers, as seen in Figure 5.2 A.
Therefore, we hypothesize that the oligomers are all dissociating under one set pathway
rather than there being two separate pathways. However, it appears to occur at different
time scales based on dissociators used. The mechanism is shown in Figure 5.2 B, where
the first paranuclei unit is very hard to pull off from the large oligomer, but once that
happens, the rest of the oligomer dissociates very fast. The fact that the dissociation
occurs rapidly after the first hexamer falls off could prevent the size change from being
observed by FCS. Although we can observe the size change in protein denaturants such
as urea and Gdn HCl. This could be due to the fact these denaturants dissociate peptides
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by weakening hydrophobic interactions and exposing hydrophobic residues; thereby
allowing us to observe the size change as the rate of dissociation is slower. In order to
validate this dissociation model more studies are needed. One attempt to investigate this
theory was the development of the TIRF method and concentration dependency studies.

Figure 5.2 Proposed mechanism of Aβ oligomer assembly (A) and disassembly (B).

While our NUNC coating experiments result did not match the expected result
according to the Wennmalm paper, our results still point to oligomer binding to sample
chamber as causing the issues of decreased fluorescence intensity and concentration
rather than dye photobleaching. Interestingly our PEG coated oligomers do not seem to
bind to the glass slide but do bind to the NUNC chamber. While experiments can be done
on the glass slide, more experiments are needed to prove our hypothesis of PEG limiting
Aβ adsorption to glass but not to the plastic NUNC due to increased surface area.
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5.2 Future Work
5.2.1 Sample adsorption experiments
As mentioned previously our experiments were not able to completely fix the
sample binding issue in the NUNC chamber. The first experiment needed, would be to
prove that using PEG is why oligomers do not stick to glass, therefore Aβ oligomers
could be prepared with and without PEG to verify this theory. Furthermore, to fix the
deviation seen in concentration of the 30nM Aβ the confocal volume should be calibrated
with both a high and low concentration of R110, which would also help verify the
concentration does not change for 30nM Aβ on glass. Second would be to use a higher
concentration and/or blocking time of PLL-PEG to try to stop binding in NUNC so that
they can be used for future experiments. Furthermore, we could try to use BSA instead of
PEG as the PEG molecules tested did not improve oligomer adsorption to the NUNC.

5.2.2 TIRF
As FCS primarily informs us about populations of oligomers, there would be
benefits to examining the individual behavior of oligomers. TIRF would allow for the
dissociation statistics across many individual oligomers within the same sample to be
analyzed. TIRF would also allow the monitoring of oligomer dissociation at significantly
faster time scales (millisecond vs minutes) to better understand if mechanistic differences
exist (linear and higher order dissociation). However, the drift effect must be avoided
before this technique can be used. If using a different fluorophore or extra wash steps do
not eliminate the drift, then the results will have to be integrated manually. This will
allow for dose-response curves on the individual oligomers to be examined. 16, 61 TIRF
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would also allow for the examination of Aβ at physiological conditions (150 mM NaCl,
and 37°C) to see if the mechanism or kinetics of dissociation change. We hypothesize
that salt and higher temperature would increase, the oligomer dissociation rate. Because
the goal is to provide insight into developing therapeutics for AD, knowing how the
conditions present in the human body effect the mechanism or kinetics of dissociation
would be valuable. TIRF would also enable the examination of the temperature
dependence on dissociation kinetics. A major advantage of the TIRF method, if
successful, would be the ability to extend this work in the future to the examination of
other amyloid systems, such as tau or amylin.

5.2.3 Complementary AFM studies
Atomic force microscopy (AFM) studies which monitors Aβ oligomer size and
concentration during small molecule induced dissociation is necessary to complement the
FCS data of oligomer dissociation. AFM is capable of characterizing size and shape of
differently sized protein aggregates at similar concentrations used for FCS. AFM does
not require fluorescent labels; therefore, AFM studies would also allow us to examine if
the fluorescein label on Aβ alters the dissociation kinetics. Similarly, the presence or lack
of PEG during oligomer formation can also be examined by AFM to determine if PEG
alters dissociation. Furthermore, AFM time course studies with the two different types of
dissociators, cooperative vs linear, would help to determine if there are two different
mechanisms of oligomer dissociation as observed by FCS.
Preliminary work with AFM was performed on FAM labeled Aβ (1-42) oligomers
deposited on mica, as outline in Appendix 3. The image obtained is shown in Figure 5.3
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below and the oligomer size agreed with the FCS result. This result shows that AFM is a
promising technique to monitor Aβ oligomer size during dissociation.

Figure 5.3 AFM image of 1:4 FAM: WT Aβ (1-42) on mica.
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APPENDICES
Appendix A. Wennmalm’s results for Aβ adsorption onto glass surfaces33
As mentioned in Ch. 3, Wennmalm, et.al, found that Aβ adsorbed onto the glass
coverslip resulting in inaccurate measurements. Their results show that when 10-30 nM
of Aβ was on untreated glass coverslips the fluorescence intensity decreased 95% in 5
minutes. Furthermore using 30 s scans they saw a continuous increase in the diffusion
coefficient. Taken together these results indicate Aβ absorption onto the glass. They were
able to limit adsorption by pretreating the glass coverslips with poly-L-lysinepolyethylene glycol (PLL-PEG), as shown in Figure A1. Their experiments were used as
the basis of our coating studies.
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Figure A1. Wennmalm showed that the fluorescence decrease was caused by oligomers
absorbing to the sample holder and this can be avoided by coating the surface with polyl-lysine PEG. Reprinted from reference: Wennmalm, S.; Chmyrov, V.; Widengren, J.;
Tjernberg, L., Highly Sensitive FRET-FCS Detects Amyloid beta-Peptide Oligomers in
Solution at Physiological Concentrations. Anal Chem 2015, 87 (23), 11700-5.
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Appendix B. Properties of Fluorescent dyes
Fluorescein

R110

Alexa

Atto 488

488
Abs /

Hilyte Fluor
488

490 / 525

498 / 520

490 / 525

504 / 521

502 / 527

425

440

430

400

430

Em
(nm)
D
(μm2/s)
Table B1: Fluorescent dye properties. 44

Figure B2: Structures of fluorescent dyes.
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Appendix C. Sample preparation for AFM studies 62-64
9.9mm diameter mica discs were immobilized on 12mm metal specimen discs
with double sided tape. Then double-sided tape was used to cleave the surface before 20
μl of FAM- labeled Aβ oligomer, see Ch.2 for protocol, was deposited on the surface and
incubated for 3 minutes. The surface was then rinsed with 0.2μm filtered DI water and
gently dried with filtered nitrogen gas. Once the sample was loaded onto the AFM a scan
rate of 1-2 Hz, with a drive amplitude 20-100mV, and set point 1-1.5 V were used to
obtain images.

82

REFERENCES
1.
2017 Alzheimer's Disease Facts and Figures Alzheimer's Association:
Alzheimers Dement, 2017; pp 325-373.
2.
Stancu, I. e. a., Models of B-amyloid induced Tau-pathology: the long and
"folded" road to understand the mechanism. Molecular Neurodegeration 2014, 9 (51).
3.
Braak, H. a. B., E, Staging of Alzheimer's Disease-Related Neurofibrillary
Changes Neurobiology of Aging 1995, 16 (3), 271-284.
4.
Ovsepian, S. V. e. a., Neuronal Activity and Amyloid Plaque Pathology: An
Update. Journal of Alzheimer’s Disease 2016, 49, 13-19.
5.
Gauthier, S.; Reisberg, B.; Zaudig, M.; Petersen, R. C.; Ritchie, K.; Broich, K.;
Belleville, S.; Brodaty, H.; Bennett, D.; Chertkow, H.; Cummings, J. L.; de Leon, M.;
Feldman, H.; Ganguli, M.; Hampel, H.; Scheltens, P.; Tierney, M. C.; Whitehouse, P.;
Winblad, B.; International Psychogeriatric Association Expert Conference on mild
cognitive, i., Mild cognitive impairment. Lancet 2006, 367 (9518), 1262-70.
6.
Alzheimer, A., About a peculiar disease of the cerebral cortex Centralblatt fur
Nervenheilkunde Psychiatrie 1907, 30, 177-179.
7.
Hippius, H.; Neundörfer, G., The discovery of Alzheimer's disease. Dialogues in
Clinical Neuroscience 2003, 5 (1), 101-108.
8.
Glenner, G. G.; Wong, C. W., Alzheimer's disease: initial report of the
purification and characterization of a novel cerebrovascular amyloid protein. Biochem
Biophys Res Commun 1984, 120 (3), 885-90.
9.
Glenner, G. G., Amyloid deposits and amyloidosis. The beta-fibrilloses (first of
two parts). The New England journal of medicine 1980, 302 (23), 1283-92.
10.
Glenner, G. G.; Wong, C. W., Alzheimer's disease and Down's syndrome: sharing
of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984,
122 (3), 1131-5.
11.
Grundke-Iqbal, I.; Iqbal, K.; Quinlan, M.; Tung, Y. C.; Zaidi, M. S.; Wisniewski,
H. M., Microtubule-associated protein tau. A component of Alzheimer paired helical
filaments. J Biol Chem 1986, 261 (13), 6084-9.
12.
Goate, A., Segregation of a missense mutation in the amyloid beta-protein
precursor gene with familial Alzheimer's disease. J Alzheimers Dis 2006, 9 (3 Suppl),
341-7.
13.
Hardy, J. A.; Higgins, G. A., Alzheimer's disease: the amyloid cascade
hypothesis. Science 1992, 256 (5054), 184-5.
14.
Pagani, L.; Eckert, A., Amyloid-Beta interaction with mitochondria. International
journal of Alzheimer's disease 2011, 2011, 925050.
15.
Prasansuklab, A.; Tencomnao, T., Amyloidosis in Alzheimer's Disease: The
Toxicity of Amyloid Beta (A beta ), Mechanisms of Its Accumulation and Implications of
Medicinal Plants for Therapy. Evid Based Complement Alternat Med 2013, 2013,
413808.
16.
Nag, S.; Sarkar, B.; Bandyopadhyay, A.; Sahoo, B.; Sreenivasan, V. K.;
Kombrabail, M.; Muralidharan, C.; Maiti, S., Nature of the amyloid-beta monomer and
the monomer-oligomer equilibrium. J Biol Chem 2011, 286 (16), 13827-33.
17.
Sengupta, U.; Nilson, A. N.; Kayed, R., The Role of Amyloid-beta Oligomers in
Toxicity, Propagation, and Immunotherapy. EBioMedicine 2016, 6, 42-49.
83

18.
Gu, L.; Guo, Z., Alzheimer's Aβ42 and Aβ40 peptides form interlaced amyloid
fibrils. Journal of neurochemistry 2013, 126 (3), 305-311.
19.
Bitan, G. e. a., Elucidation of Primary Structure Elements Controlling Early
Amyloid B-Protein Oligomerization. The Journal of Biological Chemistry 2003, 278
(37), 34882-34889.
20.
Haass, C.; Selkoe, D. J., Soluble protein oligomers in neurodegeneration: lessons
from the Alzheimer's amyloid beta-peptide. Nature reviews. Molecular cell biology 2007,
8 (2), 101-12.
21.
Benilova, I.; Karran, E.; De Strooper, B., The toxic Abeta oligomer and
Alzheimer's disease: an emperor in need of clothes. Nature neuroscience 2012, 15 (3),
349-57.
22.
Verma, M.; Vats, A.; Taneja, V., Toxic species in amyloid disorders: Oligomers
or mature fibrils. Annals of Indian Academy of Neurology 2015, 18 (2), 138-145.
23.
Kayed, R.; Lasagna-Reeves, C. A., Molecular mechanisms of amyloid oligomers
toxicity. J Alzheimers Dis 2013, 33 Suppl 1, S67-78.
24.
Johnson, R. D.; Schauerte, J. A.; Wisser, K. C.; Gafni, A.; Steel, D. G., Direct
observation of single amyloid-beta(1-40) oligomers on live cells: binding and growth at
physiological concentrations. PLoS One 2011, 6 (8), e23970.
25.
Johnson, R. D.; Schauerte, J. A.; Chang, C. C.; Wisser, K. C.; Althaus, J. C.;
Carruthers, C. J.; Sutton, M. A.; Steel, D. G.; Gafni, A., Single-molecule imaging reveals
abeta42:abeta40 ratio-dependent oligomer growth on neuronal processes. Biophys J 2013,
104 (4), 894-903.
26.
Bak, L. K., et.al. , The glutamate/GABA‐glutamine cycle: aspects of transport,
neurotransmitter homeostasis and ammonia transfer. Journal of neurochemistry 2006, 98
(3), 641-653.
27.
Rueda, C. B., et.al., Glutamate excitotoxicity and Ca2+-regulation of respiration:
Role of the Ca2+ activated mitochondrial transporters (CaMCs). Biochimica et
Biophysica Acta (BBA) - Bioenergetics, 2016, 1857 (8), 1158-1166.
28.
Hynd, M. R.; Scott, H. L.; Dodd, P. R., Glutamate-mediated excitotoxicity and
neurodegeneration in Alzheimer’s disease. Neurochemistry International 2004, 45 (5),
583-595.
29.
Viola, K. L.; Klein, W. L., Amyloid beta oligomers in Alzheimer's disease
pathogenesis, treatment, and diagnosis. Acta Neuropathol 2015, 129 (2), 183-206.
30.
RA, V., Energy inhibition elevates beta-secretase levels and activity and is
potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's
disease pathogenesis. J Neurosci. 2005, 25 (47), 10874-10883.
31.
Strittmatter, W. J.; Saunders, A. M.; Schmechel, D.; Pericak-Vance, M.; Enghild,
J.; Salvesen, G. S.; Roses, A. D., Apolipoprotein E: high-avidity binding to beta-amyloid
and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc
Natl Acad Sci U S A 1993, 90 (5), 1977-81.
32.
Nag, S.; Chen, J.; Irudayaraj, J.; Maiti, S., Measurement of the attachment and
assembly of small amyloid-beta oligomers on live cell membranes at physiological
concentrations using single-molecule tools. Biophys J 2010, 99 (6), 1969-75.
33.
Wennmalm, S.; Chmyrov, V.; Widengren, J.; Tjernberg, L., Highly Sensitive
FRET-FCS Detects Amyloid beta-Peptide Oligomers in Solution at Physiological
Concentrations. Anal Chem 2015, 87 (23), 11700-5.
84

34.
Hepler, R. W.; Grimm, K. M.; Nahas, D. D.; Breese, R.; Dodson, E. C.; Acton, P.;
Keller, P. M.; Yeager, M.; Wang, H.; Shughrue, P.; Kinney, G.; Joyce, J. G., Solution
state characterization of amyloid beta-derived diffusible ligands. Biochemistry 2006, 45
(51), 15157-67.
35.
Guan, Y.; Cao, K. J.; Cantlon, A.; Elbel, K.; Theodorakis, E. A.; Walsh, D. M.;
Yang, J.; Shah, J. V., Real-Time Monitoring of Alzheimer's-Related Amyloid
Aggregation via Probe Enhancement-Fluorescence Correlation Spectroscopy. ACS Chem
Neurosci 2015, 6 (9), 1503-8.
36.
Hayden, E. Y.; Teplow, D. B., Amyloid beta-protein oligomers and Alzheimer's
disease. Alzheimers Res Ther 2013, 5 (6), 60.
37.
LeVine, H., 3rd, Biotin-avidin interaction-based screening assay for Alzheimer's
beta-peptide oligomer inhibitors. Anal Biochem 2006, 356 (2), 265-72.
38.
Tjernberg, L. O.; Callaway, D. J.; Tjernberg, A.; Hahne, S.; Lilliehook, C.;
Terenius, L.; Thyberg, J.; Nordstedt, C., A molecular model of Alzheimer amyloid betapeptide fibril formation. J Biol Chem 1999, 274 (18), 12619-25.
39.
Novo, M. e. a., Critical aggregation concentration for the formation of early
Amyloid-B (1-42) oligomers Sci Rep 2018, 8.
40.
Mittag, J. J.; Milani, S.; Walsh, D. M.; Radler, J. O.; McManus, J. J.,
Simultaneous measurement of a range of particle sizes during Abeta1-42 fibrillogenesis
quantified using fluorescence correlation spectroscopy. Biochem Biophys Res Commun
2014, 448 (2), 195-9.
41.
LeVine, H. e. a., Dihydroxybenzoic Acid Isomers Differentially Dissociate
Soluble Biotinyl-Aβ(1–42) Oligomers. Biochemistry 2012, 51 (1), 307-315.
42.
LeVine, H., 3rd; Ding, Q.; Walker, J. A.; Voss, R. S.; Augelli-Szafran, C. E.,
Clioquinol and other hydroxyquinoline derivatives inhibit Abeta(1-42) oligomer
assembly. Neurosci Lett 2009, 465 (1), 99-103.
43.
Schwille, P., Fluorescence correlation spectroscopy: Novel variations of an
established technique. Annu. Rev. Biophys. Biomol. Struct 2007, 36, 151-169.
44.
Kapusta, P. Absolute diffusion coefficients: Compilation of reference data for
FCS (accessed October 15 ).
45.
Krieger, J. Fluorescence correlation spectroscopy.
46.
Achuthan, S.; Chung, B. J.; Ghosh, P.; Rangachari, V.; Vaidya, A., A modified
Stokes-Einstein equation for Abeta aggregation. BMC Bioinformatics 2011, 12 Suppl 10,
S13.
47.
SCH€ONLE, A., et.al., Monitoring Triplet State Dynamics With
FluorescenceCorrelation Spectroscopy: Bias and Correction. MICROSCOPY RESEARCH
AND TECHNIQUE 2014, 77, 528–536.
48.
Widengren, J. e. a., Fluorescence Correlation Spectroscopy of Triplet States in
Solution: A Theoretical and Experimental Study. J. Phys. Chem 1995, 99, 13368-13379.
49.
Davis, L., Accounting for Triplet and Saturation Effects in FCS Measurements.
Curr Pharm Biotechnol 2006, 7 (4), 287-301.
50.
Oleg Krichevsky, e. a., Fluorescence correlation spectroscopy: the technique and
its applications. Reports on Progress in Physics 2002, 65 (2).
51.
LeVine Iii, H., Alzheimer’s β-peptide oligomer formation at physiologic
concentrations. Analytical Biochemistry 2004, 335 (1), 81-90.

85

52.
Loman, A. e. a., Measuring rotational diffusion of macromolecules by
fluorescence correlation spectroscopy. Photochemical & Photobiological Sciences 2010,
9, 627-636.
53.
Monera, O. D.; Kay, C. M.; Hodges, R. S., Protein denaturation with guanidine
hydrochloride or urea provides a different estimate of stability depending on the
contributions of electrostatic interactions. Protein Science 1994, 3 (11), 1984-1991.
54.
LeVine, H., 3rd; Scholten, J. D., Screening for pharmacologic inhibitors of
amyloid fibril formation. Methods Enzymol 1999, 309, 467-76.
55.
Okamura, N.; Suemoto, T.; Furumoto, S.; Suzuki, M.; Shimadzu, H.; Akatsu, H.;
Yamamoto, T.; Fujiwara, H.; Nemoto, M.; Maruyama, M.; Arai, H.; Yanai, K.; Sawada,
T.; Kudo, Y., Quinoline and benzimidazole derivatives: candidate probes for in vivo
imaging of tau pathology in Alzheimer's disease. J Neurosci 2005, 25 (47), 10857-62.
56.
Bulic, B.; Pickhardt, M.; Khlistunova, I.; Biernat, J.; Mandelkow, E. M.;
Mandelkow, E.; Waldmann, H., Rhodanine-based tau aggregation inhibitors in cell
models of tauopathy. Angew Chem Int Ed Engl 2007, 46 (48), 9215-9.
57.
Fish, K. N., Total Internal Reflection Fluorescence (TIRF) Microscopy. Current
protocols in cytometry / editorial board, J. Paul Robinson, managing editor ... [et al.]
2009, 0 12, Unit12.18-Unit12.18.
58.
Lord, S. J.; Lee, H.-l. D.; Moerner, W. E., Single-Molecule Spectroscopy and
Imaging of Biomolecules in Living Cells. Analytical chemistry 2010, 82 (6), 2192-2203.
59.
Fox, A. M.; Moonschi, F. H.; Richards, C. I., The nicotine metabolite, cotinine,
alters the assembly and trafficking of a subset of nicotinic acetylcholine receptors. J Biol
Chem 2015, 290 (40), 24403-12.
60.
Nicholas, M. P.; Rao, L.; Gennerich, A., Covalent immobilization of microtubules
on glass surfaces for molecular motor force measurements and other single-molecule
assays. Methods Mol Biol 2014, 1136, 137-69.
61.
Gruning, C. S.; Klinker, S.; Wolff, M.; Schneider, M.; Toksoz, K.; Klein, A. N.;
Nagel-Steger, L.; Willbold, D.; Hoyer, W., The off-rate of monomers dissociating from
amyloid-beta protofibrils. J Biol Chem 2013, 288 (52), 37104-11.
62.
Jungbauer, L. M.; Yu, C.; Laxton, K. J.; LaDu, M. J., Preparation of
fluorescently-labeled amyloid-beta peptide assemblies: the effect of fluorophore
conjugation on structure and function. J Mol Recognit 2009, 22 (5), 403-13.
63.
Mastrangelo, I. A.; Ahmed, M.; Sato, T.; Liu, W.; Wang, C.; Hough, P.; Smith, S.
O., High-resolution atomic force microscopy of soluble Abeta42 oligomers. J Mol Biol
2006, 358 (1), 106-19.
64.
Stine, W. B.; Jungbauer, L.; Yu, C.; LaDu, M. J., Preparing synthetic Abeta in
different aggregation states. Methods Mol Biol 2011, 670, 13-32.

86

VITA
Hope Cook Abdalla
Place of Birth
Princeton, WV
Education
B.S. in Biochemistry, High Point University, High Point, NC, May 2012
M.S. in Chemistry, Marshall University, Huntington, WV, May 2014
Professional Experience
Teaching Assistant, University of Kentucky, Lexington, Ky.
August 2014-Dec 2018
Research Assistant, University of Kentucky, Lexington, Ky. Advisor: Dr. Jason
DeRouchey. May - August 2016, May - August 2017, May - August 2018.
Teaching Assistant, Marshall University, Huntington, WV. August 2012- Dec 2013
Research Assistant, Marshall University, Huntington, WV. Advisor: Dr. Derrick Kolling.
May 2013- May 2014
Undergraduate Researcher, High Point University, High Point, NC. Advisor: Dr. Harold
Goldston. January-May 2011
Undergraduate Researcher, High Point University, High Point, NC. Advisor: Dr. Gray
Bowman. January - Dec 2010.
Academic Honors
Dean’s List (GPA of 3.5 or higher, HPU)
Cum Laude (Graduated with GPA of 3.7, HPU)

87

